Floatz logo

Ftbi

Non-Hodgkin Lymphoma (NHL)

Stanford UniversityPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Non-Hodgkin Lymphoma (NHL) cohort.

Asset / SponsorPhaseRating
her2bbζ/cd19t+ t cells
National University Hospital, Singapore
Phase 1/2CCC
Hpc-A
St. Jude Children's Research Hospital
Phase 2CC
S 64315
Novartis Pharmaceuticals
Phase 1CC
Oriv508
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Early Phase 1C
Ratg
Everett Meyer
Phase 1/2C
Inactivated Influenza A Virus Vaccine
St. Antonius Hospital
N/AD
S-65487
Novartis Pharmaceuticals
Phase 1D

Same molecule, other indications

Ftbi is also rated in:

Hematologic DiseasesDormant
CCC
Indicative ·
53 / 100
View asset →
Acute-graft-versus-host DiseaseDormant
CCC
Indicative ·
53 / 100
View asset →
LeukemiaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →